This study, called GLUCOSE-MGH, aims to understand how your genes affect your body's response to oral semaglutide (Rybelsus), a medication approved for type 2 diabetes. Researchers also want to see how your body reacts to a special breakfast meal before and after taking oral semaglutide. You would take 7 mg of oral semaglutide once daily for 14 days. To join, you need to be between 18 and 65 years old and have blood sugar levels that fall between normal and pre-diabetes. The main goal is to measure how your body's insulin responds to oral semaglutide treatment after 15 days. The study is currently unclear on its recruitment status and plans to enroll 125 participants.

Study design

This is an interventional study planning to enroll 125 participants. It involves taking oral semaglutide and undergoing specific tests.

What's involved

You would have two visits to the clinic. During these visits, you'll have blood drawn multiple times after eating a standardized breakfast meal. You will also take oral semaglutide daily for 14 days between visits.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for measuring insulin response is at 15 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.